Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders
Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology..
BACKGROUND AND OBJECTIVES: To investigate whether children receiving immunosuppressive therapies for neuroimmunologic disorders had (1) increased susceptibility to SARS-CoV2 infection or to develop more severe forms of COVID-19; (2) increased relapses or autoimmune complications if infected; and (3) changes in health care delivery during the pandemic.
METHODS: Patients with and without immunosuppressive treatment were recruited to participate in a retrospective survey evaluating the period from March 14, 2020, to March 30, 2021. Demographics, clinical features, type of immunosuppressive treatment, suspected or confirmed COVID-19 in the patients or cohabitants, and changes in care delivery were recorded.
RESULTS: One hundred fifty-three children were included: 84 (55%) female, median age 13 years (interquartile range [8-16] years), 79 (52%) on immunosuppressive treatment. COVID-19 was suspected or confirmed in 17 (11%) (all mild), with a frequency similar in patients with and without immunosuppressive treatment (11/79 [14%] vs 6/74 [8%], p = 0.3085). The frequency of neurologic relapses was similar in patients with (18%) and without (21%) COVID-19. Factors associated with COVID-19 included having cohabitants with COVID-19 (p < 0.001) and lower blood levels of vitamin D (p = 0.039). Return to face-to-face schooling or mask type did not influence the risk of infection, although 43(28%) children had contact with a classmate with COVID-19. Clinic visits changed from face to face to remote for 120 (79%) patients; 110 (92%) were satisfied with the change.
DISCUSSION: In this cohort of children with neuroimmunologic disorders, the frequency of COVID-19 was low and not affected by immunosuppressive therapies. The main risk factors for developing COVID-19 were having cohabitants with COVID-19 and low vitamin D levels.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Neurology(R) neuroimmunology & neuroinflammation - 9(2022), 1 vom: 15. Jan. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Olivé-Cirera, Gemma [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1406-16-2 |
|---|
| Anmerkungen: |
Date Completed 25.11.2021 Date Revised 08.11.2023 published: Electronic-Print Citation Status MEDLINE |
|---|
| doi: |
10.1212/NXI.0000000000001101 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332969495 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332969495 | ||
| 003 | DE-627 | ||
| 005 | 20231225220652.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1212/NXI.0000000000001101 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1109.xml |
| 035 | |a (DE-627)NLM332969495 | ||
| 035 | |a (NLM)34759018 | ||
| 035 | |a (PII)e1101 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Olivé-Cirera, Gemma |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Impact of COVID-19 in Immunosuppressed Children With Neuroimmunologic Disorders |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.11.2021 | ||
| 500 | |a Date Revised 08.11.2023 | ||
| 500 | |a published: Electronic-Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. | ||
| 520 | |a BACKGROUND AND OBJECTIVES: To investigate whether children receiving immunosuppressive therapies for neuroimmunologic disorders had (1) increased susceptibility to SARS-CoV2 infection or to develop more severe forms of COVID-19; (2) increased relapses or autoimmune complications if infected; and (3) changes in health care delivery during the pandemic | ||
| 520 | |a METHODS: Patients with and without immunosuppressive treatment were recruited to participate in a retrospective survey evaluating the period from March 14, 2020, to March 30, 2021. Demographics, clinical features, type of immunosuppressive treatment, suspected or confirmed COVID-19 in the patients or cohabitants, and changes in care delivery were recorded | ||
| 520 | |a RESULTS: One hundred fifty-three children were included: 84 (55%) female, median age 13 years (interquartile range [8-16] years), 79 (52%) on immunosuppressive treatment. COVID-19 was suspected or confirmed in 17 (11%) (all mild), with a frequency similar in patients with and without immunosuppressive treatment (11/79 [14%] vs 6/74 [8%], p = 0.3085). The frequency of neurologic relapses was similar in patients with (18%) and without (21%) COVID-19. Factors associated with COVID-19 included having cohabitants with COVID-19 (p < 0.001) and lower blood levels of vitamin D (p = 0.039). Return to face-to-face schooling or mask type did not influence the risk of infection, although 43(28%) children had contact with a classmate with COVID-19. Clinic visits changed from face to face to remote for 120 (79%) patients; 110 (92%) were satisfied with the change | ||
| 520 | |a DISCUSSION: In this cohort of children with neuroimmunologic disorders, the frequency of COVID-19 was low and not affected by immunosuppressive therapies. The main risk factors for developing COVID-19 were having cohabitants with COVID-19 and low vitamin D levels | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 650 | 7 | |a Vitamin D |2 NLM | |
| 650 | 7 | |a 1406-16-2 |2 NLM | |
| 700 | 1 | |a Fonseca, Elianet |e verfasserin |4 aut | |
| 700 | 1 | |a Cantarín-Extremera, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Vázquez-López, María |e verfasserin |4 aut | |
| 700 | 1 | |a Jiménez-Legido, María |e verfasserin |4 aut | |
| 700 | 1 | |a González-Álvarez, Verónica |e verfasserin |4 aut | |
| 700 | 1 | |a Ribeiro-Constante, Juliana |e verfasserin |4 aut | |
| 700 | 1 | |a Camacho-Salas, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Martí, Itxaso |e verfasserin |4 aut | |
| 700 | 1 | |a Cancho-Candela, Ramon |e verfasserin |4 aut | |
| 700 | 1 | |a Martínez-González, María Jesús |e verfasserin |4 aut | |
| 700 | 1 | |a Saiz, Albert |e verfasserin |4 aut | |
| 700 | 1 | |a Armangué, Thaís |e verfasserin |4 aut | |
| 700 | 0 | |a Spanish Study Group NeuroimmunoPed-Covid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurology(R) neuroimmunology & neuroinflammation |d 2014 |g 9(2022), 1 vom: 15. Jan. |w (DE-627)NLM243009216 |x 2332-7812 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2022 |g number:1 |g day:15 |g month:01 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1212/NXI.0000000000001101 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2022 |e 1 |b 15 |c 01 | ||